Theralase(R) Technology Effective in Virus Inactivation
TORONTO, ON / ACCESSWIRE / June 4, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Month: June 2024
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT...
Zomedica Increases Manufacturing Capacity with Expansion of its Roswell, Georgia Facility; Can Support Production to Five times Current Levels
Timely expansion enhances capacity amidst rapid sales growth ANN ARBOR, MI / ACCESSWIRE / June 4, 2024 / Zomedica Corp....
BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company...
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
Predictive Oncology’s organ-specific in vitro models are designed to better mimic the physiological environment of human tissue The 3D cell culture...
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1Anticipate potential proof-of-concept data available in the first half...
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
ART26.12 shows efficacy in breast cancer-induced bone pain and diabetic neuropathySOLANA BEACH, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Artelo...
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
HOUSTON, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced today...
XORTX to Present at BIO International Convention 2024
CALGARY, June 04, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX |...
Inspire Medical Systems, Inc. to Present at the Truist Securities Medtech Conference
MINNEAPOLIS, June 04, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on...
iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference
NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create...
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today...
Bitterroot Bio Announces Appointment of Georgette Verdin as Chief People Officer and Sherwin Chen as Chief Legal Officer and Corporate Secretary
PALO ALTO, Calif. and NEEDHAM, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a pioneering biotechnology company focused on...
American Oncology Network Announces the Research Studies Presented at the ASCO 2024 Annual Meeting
AON physicians and leaders present their latest cancer findings with fellow thought leaders at the annual conference. American Oncology Network...
STRATA Skin Sciences to Participate in June Dermatology Conferences
HORSHAM, Penn., June 04, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical...
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024...
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its...
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+...
The MUHC Foundation’s Le Bal Rouge Gala Raises a record-breaking $2,050,000 million for Cancer Research at the MUHC
The MUHC Foundation backs the most innovative cancer researchers in the province. This year’s Le Bal Rouge gala supported the...
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company...